Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

BMI Feasible As Pre-Screening Tool for Osteoporosis in Women

Larry Hand  |  

NEW YORK (Reuters Health)—A body mass index (BMI) of less than 28 alone may be a tool to prescreen younger postmenopausal women for osteoporosis, according to a new study. “For young postmenopausal white women aged 50–64, current prescreening modalities identifying candidates for DXA (dual-energy X-ray absorptiometry) scan … are not performing better than BMI alone,”…

FDA Reviewers Question Safety of AstraZeneca’s Gout Drug

Amrutha Penumudi  |  

(Reuters)—The U.S. Food and Drug Administration staff reviewers have raised concerns about kidney- and heart-related side effects noted in trials on AstraZeneca Plc’s gout treatment, especially at higher doses. FDA reviewers, in a preliminary review published on Wednesday, expressed concerns over higher death rates related to the side effects in patients who took the drug,…

Knee Replacement Surgery Works, but So Can Nonsurgical Techniques

Gene Emery  |  

(Reuters Health)—Total knee replacement can usually relieve pain and improve function, but a nonsurgical regimen can also be effective in some people without posing the complication risks of surgery, according to a new study. The study found that while 85% of patients who underwent surgery showed clinically-significant improvement after one year, so did 67% assigned…

Even Doctors & Nurses Don’t Always Have Healthy Lifestyles

Lisa Rapaport  |  

NEW YORK (Reuters Health)—Even doctors and nurses don’t always follow the healthy lifestyle choices they recommend for patients to reduce the risk of medical problems, such as obesity, heart disease and diabetes, a U.S. study suggests. Although rates of these conditions appeared lower among healthcare workers than other people, the diseases were still common. They…

J&J’s Stelara Succeeds in Phase 3 Crohn’s Disease Trial

Bill Berkrot  |  

(Reuters)—Johnson & Johnson’s Stelara (ustekinumab) was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat plaque psoriasis…

Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

Lorraine L. Janeczko  |  

NEW YORK (Reuters Health)—Rituximab may calm juvenile idiopathic arthritis (JIA)-associated uveitis and especially benefit patients who haven’t responded to other biologic treatments, a study from Italy suggests. With its convenient dosing schedule, rituximab may be a new treatment option for patients with autoimmune diseases, especially for those who have not responded to tumor necrosis factor…

Use of Unspecified Codes in ICD-10: What You Need to Know

From the College  |  

The ACR Practice Management and Coding department will periodically update the membership on the new ICD-10 coding guidelines and conventions to assist practices with accurate billing. Our top question during the first week of ICD-10 implementation was on the use of unspecified codes…

Hospital-Owned Physician Practices Linked to Higher Prices

Lisa Rapaport  |  

(Reuters Health)—Outpatient care may cost more when hospitals own the medical practices or employ the physicians, a U.S. study suggests. Hospital employment of doctors and ownership of physician practices has grown over the past decade as healthcare providers seek to curb expenses with economies of scale and deliver better coordinated treatment to patients. Research reported…